Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Selumetinib
CAS 606143-52-6
Smetinib, developed by AstraZeneca, UK, is used to treat advanced non-small cell lung cancer. Smetinib inhibits the growth of a variety of tumors, including melanoma with b-raf-mutation and non-small cell lung cancer with K-ras mutation (NSCLC), mainly by regulating the level of key protein kinase MEK in the RA Raf-MEK-ERK pathway. It is mainly used for the treatment of cholangiocarcinoma, colorectal cancer and NSCLC. At present, smetinib is in the phase III clinical trial of non-small cell lung cancer.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
